Protein Expression in Down Syndrome Brain

Front Matter....Pages I-X
Decreased alpha-endosulfine, an endogenous regulator of ATP-sensitive potassium channels, in brains from adult Down syndrome patients....Pages 1-9
Developmental instability of the cerebellum and its relevance to Down syndrome....Pages 11-34
Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains....Pages 35-45
Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down Syndrome....Pages 47-57
Fetal life in Down Syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure....Pages 59-70
Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome....Pages 71-84
Glial-neurotrophic mechanisms in Down syndrome....Pages 85-94
Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down Syndrome brain....Pages 95-107
Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains....Pages 109-116
Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome....Pages 117-130
Functional genomics of Down syndrome: a multidisciplinary approach....Pages 131-148
Unaltered expression of Fas (CD95/APO-1), Caspase-3, Bcl-2 and Annexins in brains of fetal Down syndrome: evidence against increased apoptosis....Pages 149-162
Alteration of caspases and other apoptosis regulatory proteins in Down syndrome....Pages 163-179
Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF- k B in brains of patients with Down syndrome....Pages 181-192
Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down Syndrome and Alzheimer’s disease....Pages 193-201
Carbohydrate handling enzymes in fetal Down Syndrome brain....Pages 203-210
Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer’s disease....Pages 211-222
Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down Syndrome....Pages 223-235
Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome....Pages 237-245
The brain in Down syndrome....Pages 247-261
Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer’s disease....Pages 263-272
Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains....Pages 273-280
Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer’s disease....Pages 281-288
Molecular neuropathology of transgenic mouse models of Down syndrome....Pages 289-301
Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation....Pages 303-310
Expression profiles of proteins in fetal brain with Down syndrome....Pages 311-319
Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down Syndrome: dysregulation of T-complex protein 1....Pages 321-334
β-Amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect....Pages 335-346
Reduction of nucleoside diphosphate kinase B, Rab GDP- dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down Syndrome brain....Pages 347-359
Alteration of gene expression in Down’s syndrome (DS) brains: its significance in neurodegeneration....Pages 361-371
Back Matter....Pages 373-374